Latest Ratios: P/E Ratio -4.9x · EV/EBITDA N/A · ROE -11.9%. (2009–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $37M | $76M | $28M | — | — | — | — | — | — | — | — |
| Enterprise Value | $20M | $59M | $5M | — | — | — | — | — | — | — | — |
| P/E Ratio → | -4.89 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.59 | 1.20 | 0.41 | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | 61.2% | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | -8377.1% | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | -10039.8% | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -11.9% | -11.9% | -21.2% | -26.9% | -65.1% | -13.8% | -70.3% | -346.6% | -452.1% | -147.1% | -43.5% |
| ROA | -11.2% | -11.2% | -18.8% | -22.9% | -55.2% | -11.8% | -56.1% | -147.3% | -144.0% | -90.3% | -39.4% |
| ROIC | -18.2% | -18.2% | -42.8% | -33.0% | -89.1% | -34.7% | -879.2% | — | — | -123.2% | -33.6% |
| ROCE | -16.5% | -16.5% | -33.5% | -23.7% | -70.2% | -19.3% | -52.7% | -216.7% | -192.1% | -101.4% | -41.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.01 | 0.00 | 0.00 | 0.01 | 0.12 | 0.20 | 0.06 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.27 | -0.33 | -0.37 | -0.40 | -0.28 | -0.91 | -1.08 | -1.40 | -0.80 | 0.06 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -50.99 | -121.90 | -37.20 | -44.05 | -193.28 |
Net cash position: cash ($17M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.10 | 8.10 | 11.77 | 14.26 | 8.59 | 13.97 | 39.50 | 2.16 | 2.05 | 1.42 | 4.76 |
| Quick Ratio | 8.10 | 8.10 | 11.77 | 14.26 | 8.59 | 13.97 | 39.50 | 2.16 | 2.05 | 1.42 | 4.76 |
| Cash Ratio | 7.91 | 7.91 | 11.47 | 13.66 | 8.18 | 13.39 | 38.46 | 2.86 | 1.88 | 1.23 | — |
| Asset Turnover | — | — | — | — | — | — | 0.00 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | 785.67 | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $17M | $12M | $10M | $7M | $6M | $2M | $2M | $1M | $364302 | $231135 |
Binary clinical trial outcome
According to market data, GRCE trades at a price-to-book ratio of 0.60, which reflects a significant discount compared to peers like ACADIA Pharmaceuticals, suggesting the market heavily discounts the company's intangible assets due to the high uncertainty surrounding its current clinical-stage pipeline and future commercial viability.
The negative P/E ratio of -4.98 is a standard feature for pre-revenue biotechnology firms, yet the low P/B ratio indicates that investors are assigning little value to the company's intellectual property. This valuation gap suggests that the market is pricing in a high probability of further equity dilution or potential failure of the GTX-104 program.
Based on reported financial figures, GRCE has consistently generated negative ROIC, with the most recent quarterly reading of -4.8% highlighting the firm's inability to deploy capital efficiently while it remains in a pre-commercial state without any revenue to offset its substantial research and development expenditures.
The trend of negative returns on capital is structural rather than cyclical, as the company lacks the operational scale to generate positive margins. Investors should monitor whether the company can achieve a positive inflection point in capital efficiency once clinical milestones are met, though current trends indicate ongoing value destruction.
As reported in recent SEC filings, the company maintains a current ratio of 8.10, which appears superficially strong but is misleading given the firm's lack of revenue and the high, ongoing cash burn required to fund late-stage clinical trials for its lead therapeutic candidate, GTX-104.
While the high current ratio suggests an ability to meet short-term obligations, it does not account for the massive, non-discretionary clinical trial costs that will rapidly deplete these reserves. The liquidity position is therefore highly vulnerable to any regulatory delays that would extend the time to market and necessitate additional capital raises.
As indicated by the company's financial statements, the current ratio is the most commonly misapplied metric for GRCE, as it obscures the reality that the firm's assets are primarily cash being consumed by R&D rather than working capital supporting a sustainable, revenue-generating business model.
Analysts should instead focus on the 'cash runway' metric, which measures the number of months the company can survive at its current burn rate. Relying on standard liquidity ratios like the current or quick ratio provides a false sense of security that ignores the binary nature of the company's clinical development risks.
Includes 30+ ratios · 18 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GRCE stock.
Grace Therapeutics, Inc.'s current P/E ratio is -4.9x. This places it at the 50th percentile of its historical range.
Grace Therapeutics, Inc.'s return on equity (ROE) is -11.9%. The historical average is -88.0%.
Based on historical data, Grace Therapeutics, Inc. is trading at a P/E of -4.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.